Current Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2010 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.
Journal Article Ann Surg Oncol · July 2025 BACKGROUND: Adjuvant therapies reduce recurrence in patients with clinical stage IIB/IIC/III melanoma; however, better risk stratification and patient selection are needed. Circulating tumor DNA (ctDNA) as a marker of micrometastatic residual disease is be ... Full text Link to item CiteA comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases.
Journal Article Acta Neuropathol Commun · June 2, 2025 BACKGROUND: Melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biological features and clinical outcomes of MBM will facilitate the design of rational therapies. METHODS: We examine ... Full text Link to item CiteSymptomatic Necrosis With Dual Immune-Checkpoint Inhibition and Radiosurgery for Brain Metastases.
Journal Article JAMA Netw Open · April 1, 2025 Full text Link to item CiteRecent Grants
A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Clinical TrialPrincipal Investigator · Awarded by Linnaeus Therapeutics, Inc. · 2025 - 2030A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma R3767-ONC-2208
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029Replimune RP2-202: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naive Adult Patients with Inoperab
Clinical TrialPrincipal Investigator · Awarded by Replimune, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
University of North Carolina, Chapel Hill ·
2004
M.D.